
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

NEXTCURE, INC.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

65343E207

(CUSIP Number)

06/20/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 65343E207

Names of Reporting Persons

1

Simcere Zaiming, Inc.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares 5 Sole Voting Power

Beneficially 338,636.00
Owned by Shared Voting Power
Each 6
Reporting 0.00
Person
With: Sole Dispositive Power
7
338,636.00
Shared Dispositive
8 Power
0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

12.7 %

Type of Reporting Person (See Instructions)

12

CO

Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

SCHEDULE 13G

CUSIP No. 65343E207

Names of Reporting Persons

1

Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

CHINA

Sole Voting Power

5

338,636.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by

0.00

Each
Reporting

Sole Dispositive Power

7

Person
With:

338,636.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

338,636.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11 12.7 %

Type of Reporting Person (See Instructions)

12 CO

Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

SCHEDULE 13G

CUSIP No. 65343E207

Names of Reporting Persons

1 Hainan Simcere Zaiming Pharmaceutical Co., Ltd.

Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 CHINA

Sole Voting Power

5

338,636.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6

0.00

Sole Dispositive Power

7

338,636.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 12.7 %

Type of Reporting Person (See Instructions)

12 CO

Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is

100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Hainan Simcere Zaiming Pharmaceutical Co., Ltd. may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

SCHEDULE 13G

CUSIP No. 65343E207

Names of Reporting Persons

1 Simcere Pharmaceutical Group Limited

Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 CHINA

Sole Voting Power

5 338,636.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power

0.00

Sole Dispositive Power

7 338,636.00

Shared Dispositive

8 Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 12.7 %

Type of Reporting Person (See Instructions)

12 CO

Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Simcere Pharmaceutical Group Limited is the controlling shareholder of Hainan Simcere Zaiming Pharmaceutical Co., Ltd. through investment in several intermediate companies. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Pharmaceutical Group Limited may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc. Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

Names of Reporting Persons

1

Ren Jinsheng

Check the appropriate box if a member of a Group (see instructions)

2

 (a) (b)

3

Sec Use Only

Citizenship or Place of Organization

4

CHINA

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

338,636.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

338,636.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

12.7 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Pharmaceutical Group Limited and a director of Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Renhong Tang. Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

SCHEDULE 13G

Names of Reporting Persons

1

Tang Renhong

Check the appropriate box if a member of a Group (see instructions)

2

 (a) (b)

3 Sec Use Only
Citizenship or Place of Organization

4 CHINA

Sole Voting Power

5
0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6
338,636.00

Sole Dispositive Power

7
0.00

8
Shared Dispositive Power

338,636.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9
338,636.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

11
12.7 %

Type of Reporting Person (See Instructions)

12
IN

Comment for Type of Reporting Person: Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Pharmaceutical Group Limited, the chief executive officer and chairman of the board of directors of Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. and the chief executive officer and sole director of Simcere Zaiming, Inc. Accordingly, Mr. Renhong Tang may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Jinsheng Ren. Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

SCHEDULE 13G

Item 1.

Name of issuer:

(a) NEXTCURE, INC.

Address of issuer's principal executive offices:

(b) 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705

Item 2.

(a) Name of person filing:

(i) Simcere Zaiming, Inc., a Delaware corporation ("Simcere Zaiming"), with its principal business address at 20 Acorn Park Dr., Cambridge, MA 02140; (ii) Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Jiangsu Zaiming"), is the sole shareholder of Simcere Zaiming, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; (iii) Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Hainan Zaiming"), is the sole shareholder of Jiangsu Zaiming, and its principal business address is at No 20, Yaoguyiheng Road, Xiuying District, Haikou, Hainan, P. R. China. (iv) Simcere Pharmaceutical Group Limited, a company incorporated in Hong Kong ("Simcere Group") and the controlling shareholder of Hainan Zaiming through several intermediate companies, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing,

Jiangsu, P. R. China. (v) Mr. Jinsheng Ren, citizen of People's Republic of China, the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; and (vi) Mr. Renhong Tang, citizen of People's Republic of China, a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China. The persons and entities listed in items (i) to (vi) are collectively referred to herein as "Reporting Persons." The Reporting Persons have entered into a joint filing agreement, a copy of which is attached hereto as Exhibit 99.1. Address or principal business office or, if none, residence:

(b)

See Item 2(a) above.

Citizenship:

(c)

See Item 2(a) above.

Title of class of securities:

(d)

Common Stock, par value \$0.001 per share

CUSIP No.:

(e)

65343E207

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) See Row 9 of the cover page for each Reporting Person. Each of Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this Schedule 13G shall not be deemed to be an admission that the Reporting Persons hereunder are the beneficial owners of any of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Percent of class:

(b)

See Row 11 of the cover page for each Reporting Person. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Row 5 of the cover page for each Reporting Person.

(ii) Shared power to vote or to direct the vote:

See Row 6 of the cover page for each Reporting Person.

(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of the cover page for each Reporting Person.

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of the cover page for each Reporting Person.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sincere Zaiming, Inc.

Signature: /s/ Renhong Tang

Name/Title: Renhong Tang/Chief Executive Officer

Date: 08/19/2025

Jiangsu Sincere Zaiming Pharmaceutical Co., Ltd.

Signature: /s/ Renhong Tang

Name/Title: Renhong Tang/Director and Attorney-in-Fact

Date: 08/19/2025

Hainan Sincere Zaiming Pharmaceutical Co., Ltd.

Signature: /s/ Renhong Tang

Name/Title: Renhong Tang/Chief Executive Officer and
Chairman of the Board of Directors

Date: 08/19/2025

Sincere Pharmaceutical Group Limited

Signature: /s/ Jinsheng Ren

Name/Title: Jinsheng Ren / Chief Executive Officer and
Chairman of the Board of Directors

Date: 08/19/2025

Ren Jinsheng

Signature: /s/ Jinsheng Ren

Name/Title: Jinsheng Ren

Date: 08/19/2025

Tang Renhong

Signature: /s/ Renhong Tang

Name/Title: Renhong Tang

Date: 08/19/2025

Exhibit Information

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Mr. Renhong Tang, a director of the undersigned, with full power of substitution and re-substitution, as the undersigned's true and lawful attorney-in-fact (referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

1. execute for and on behalf of the undersigned, in the undersigned's capacity as the Legal Presentative and Chairman of the Board of Directors of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in the P. R. China (the "Company"), any and all forms, schedules, statements and other documents (including any amendments thereto) ("Filings") that the Company may be required to file with the U.S. Securities and Exchange Commission ("SEC") under (i) Section 13 or Section 16 of the U.S. Securities Exchange Act of 1934, as amended, and any rule or regulation thereunder, including without limitation filings on Form 3, Form 4, Form 5, Schedule 13D and Schedule 13G; and (ii) the U.S. Securities Act of 1933, as amended, and Rule 144 thereunder, including without limitations filings on Form 144.
2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Filings identified in sub-paragraph (1) above, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the Company, it being understood that the documents executed by such Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such Attorney-in-Fact may approve in such Attorney-in-Fact's discretion.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney. The undersigned acknowledges that the Attorneys-in-Fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with the U.S. Securities Exchange Act of 1934, as amended, or any rules thereunder, or the U.S. Securities Act of 1933, as amended, or any rules thereunder.

This Power of Attorney shall remain in full force and effect until the Company is no longer required to make any such Filings, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of August 8, 2025.

[Signature Page to Follow]

Jiangsu Sincere Zaiming Pharmaceutical Co., Ltd.

By: /s/ Wu Yongmin

Name: Wu Yongmin

Title: Legal Representative and
Chairman of the Board of Directors

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value \$0.001 per share, of NextCure, Inc. is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: August 19, 2025

Sincere Zaiming, Inc.

By: /s/ Renhong Tang
Name: Renhong Tang
Title: Chief Executive Officer

Jiangsu Sincere Zaiming Pharmaceutical Co., Ltd.

By: /s/ Renhong Tang
Name: Renhong Tang
Title: Director and Attorney-in-Fact

Hainan Sincere Zaiming Pharmaceutical Co., Ltd.

By: /s/ Renhong Tang
Name: Renhong Tang
Title: Chief Executive Officer and
Chairman of the Board of Directors

Sincere Pharmaceutical Group Limited

By: /s/ Jinsheng Ren
Name: Jinsheng Ren
Title: Chief Executive Officer and
Chairman of the Board of Directors

Jinsheng Ren

By: /s/ Jinsheng Ren
Name: Jinsheng Ren

Renhong Tang

By: /s/ Renhong Tang
Name: Renhong Tang